The President of the Government of Spain meets with Roche CEO to discuss the upcoming investments in Spain and the current state of the pharmaceutical sector

Meeting between the President of the Government of Spain, Pedro Sánchez, and the CEO of the pharmaceutical group Roche, Thomas Schinecker, at Moncloa Palace (Pool Moncloa / Javier Amescua)

The President of the Government of Spain, Pedro Sánchez, has held a meeting at the Moncloa Palace with the CEO of the pharmaceutical group Roche, Thomas Schinecker, who shared details of a new agreement which will be signed in the coming days with Rovi, to manufacture a new drug entirely in Spain to treat type II diabetes and obesity.

At the meeting, which was also attended by Rovi CEO, Juan López-Belmonte, and Roche Spain's general manager, Patrick Wallach, Thomas Schinecker explained that they will collaborate to manufacture a new treatment, in advanced clinical development, which will be marketed worldwide. The initiative will create skilled jobs and boost Spain's capacity in the field of biomedical innovation, in addition to generating an economic impact on the country of more than 2 billion euros.

Roche's CEO thanked the President of the Government of Spain for the government's support for the sector. In recent years, industrial policies have been promoted that place Spain at the forefront of state-of-the-art pharmaceutical production: these range from the Pharmaceutical Industry Strategy 2024-2028, to boost Spain's strategic autonomy, to the specific lines of action developed with the Recovery, Transformation and Resilience Plan. In addition, the Government maintains its firm commitment to public-private partnership and the attraction of foreign investment, as drivers of the economy, the generation of quality employment and the promotion of scientific and technical knowledge.

Non official translation